- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04442646
Role of "Asthma School" in Disease Management
April 23, 2026 updated by: Istituti Clinici Scientifici Maugeri SpA
According to the definition provided by the GINA guidelines, asthma is characterized by a variable and reversible limitation of expiratory airflow and by the following symptoms: wheezing, dyspnoea, thoracic constriction and/or cough.
The type and the severity of airflow limitation can vary over time (1) depending on external agents, such as physical exercise, polluting agents, climate changes and viral infections.
The therapy is mainly based on the use of inhaled corticosteroids and bronchodilators.
Patients affected by severe asthma (~ 10% of total prevalence of asthma and at high risk of exacerbations and/or hospitalization) may not control their symptoms, even if exposed to maximal doses of inhalation therapy.The behavioural sciences can potentially help to find the psychological factors behind scarce adherence and to develop strategies with the aim of improving the interactive processes between patients, medical doctors and health care professionals
Study Overview
Detailed Description
Asthma is a chronic inflammatory disease affecting 300 million people worldwide, especially children.
In Italy, asthma affects 3 million patients and represents one of the main expenses of the Italian National Heath Care Service.
According to the definition provided by the GINA guidelines, asthma is characterized by a variable and reversible limitation of expiratory airflow and by the following symptoms: wheezing, dyspnoea, thoracic constriction and/or cough.
The type and the severity of airflow limitation can vary over time (1) depending on external agents, such as physical exercise, polluting agents, climate changes and viral infections.
The therapy is mainly based on the use of inhaled corticosteroids and bronchodilators.
Patients affected by severe asthma (~ 10% of total prevalence of asthma and at high risk of exacerbations and/or hospitalization) may not control their symptoms, even if exposed to maximal doses of inhalation therapy.
More than one third of severe asthma patients receive oral corticosteroids prescriptions, with the risk of severe and irreversible adverse events.
Therapy adherence is generally poor when therapeutic regimes are prescribed for chronic diseases, including asthma (4).
The behavioural sciences can potentially help to find the psychological factors behind scarce adherence and to develop strategies with the aim of improving the interactive processes between patients, medical doctors and health care professionals (4).
Several studies have described intervention models focused on education of the patients to symptoms and exacerbations recognition, therapy management, reduction of the exposure to trigger agents and improvement of social and physical activities (5-6).
The intervention is not able to make patients independent in disease managing, but can improve the cooperation in asthma management.
Another important aspect in asthma management is the quality of the therapeutic intervention: the correct delivery of inhalation therapy is the key for the disease control (3).
Specific educational intervention such as "asthma school" can improve symptoms control and reduce; however, up to day, a universal and standardized protocol is not available and further studies are needed.
Study Type
Interventional
Enrollment (Estimated)
92
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Dina Visca, Prof.
- Phone Number: 0331829599
- Email: dina.visca@icsmaugeri.it
Study Locations
-
-
Lombardy
-
Tradate, Lombardy, Italy, 21049
- Recruiting
- Istituti Clinici Maugeri Pneumologia
-
Contact:
- Dina Visca
- Phone Number: +390331829409
- Email: dina.visca@icsmaugeri.it
-
Sub-Investigator:
- Antonio Spanevello, MD
-
Contact:
- Francesca Cherubino
- Phone Number: +390331829599
- Email: francesca.cherubino@icsmaugeri.it
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Asthma diagnosis according to GINA / ATS guidelines.
- Age ≥18 years
Exclusion Criteria:
•cognitive impairment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ASG= Asthma School Group, with educational intervention
experimental "asthma school" group (ASG) will attend control visits as Control Group every three months.
In addiction, ASG will attend 3 further meetings consisting in multidisciplinary lessons (pneumologist, nurse, biologist and respiratory therapist) once a week within 1 month after randomization.
Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary.
Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
|
the multidisciplinary lessons will be conducted by study staff, formed by pneumologist, nurse, biologist and respiratory therapist once a week within 1 month after randomization.
Study staff will deal with the following topics: asthma physiopathology, recognition of asthma symptoms and exacerbation, educational interventions on therapy and device, nutritional counselling if necessary.
Patients will receive a paper diary for symptoms and an expiratory pick flow meter (PFM) to be done twice a day
|
|
No Intervention: CG= Control Group, With no educational intervention
Control group will attend control visits every three months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of exacerbations
Time Frame: 2 years
|
number of exacerbations in a period of 12 months in asthmatic subjects belonging to experimental group compared to controls.
|
2 years
|
|
ER accesses
Time Frame: 2 years
|
ER accesses in a period of 12 months in asthmatic subjects belonging to experimental group compared to controls.
|
2 years
|
|
number of asthma related hospitalizations
Time Frame: 2 years
|
number of asthma related hospitalizations in a period of 12 months in asthmatic subjects belonging to experimental group compared to controls.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Asthma control test ACT (0-25)
Time Frame: 2 years
|
evaluating asthma symptoms control in Asthma School Group (ASG) compared to Control Group (CG).
|
2 years
|
|
Asthma control questionnaire ACQ (0-6)
Time Frame: 2 years
|
evaluating asthma symptoms control in Asthma School Group (ASG) compared to Control Group (CG).
|
2 years
|
|
St. George Respiratory questionnaire SGRQ (0-100)
Time Frame: 2 years
|
assessing quality of life in Asthma School Group (ASG) compared to Control Group (CG).
|
2 years
|
|
airways and systemic inflammation
Time Frame: 2 years
|
differential cell count in sputum and blood in Asthma School Group (ASG) compared to Control Group (CG).
Sputum inflammatio: number eosinophills >3%, sistemic inflammation: eosiniphils cell count >250 cell/ul
|
2 years
|
|
respiratory function
Time Frame: 2 years
|
Forced Expiratory Volume in 1 second (FEV1) l, %, Forced Volume Capacity (FVC) l,%, FEV1 / FVC% values in Asthma School Group (ASG) compared to Control Group (CG).
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Antonio Spanevello, Prof, ICS Maugeri
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Nair AS, DeMuth K, Chih-Wen Cheng, Wang MD. Asthma Academy: Developing educational technology to improve Asthma medication adherence and intervention efficiency. Annu Int Conf IEEE Eng Med Biol Soc. 2017 Jul;2017:1364-1367. doi: 10.1109/EMBC.2017.8037086.
- Klijn SL, Hiligsmann M, Evers SMAA, Roman-Rodriguez M, van der Molen T, van Boven JFM. Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir Med. 2017 Apr 13;27(1):24. doi: 10.1038/s41533-017-0022-1.
- Muhlhauser I, Richter B, Kraut D, Weske G, Worth H, Berger M. Evaluation of a structured treatment and teaching programme on asthma. J Intern Med. 1991 Aug;230(2):157-64. doi: 10.1111/j.1365-2796.1991.tb00424.x.
- Ringsberg KC, Wiklund I, Wilhelmsen L. Education of adult patients at an "asthma school": effects on quality of life, knowledge and need for nursing. Eur Respir J. 1990 Jan;3(1):33-7.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2019
Primary Completion (Estimated)
December 15, 2026
Study Completion (Estimated)
December 15, 2026
Study Registration Dates
First Submitted
June 19, 2020
First Submitted That Met QC Criteria
June 19, 2020
First Posted (Actual)
June 22, 2020
Study Record Updates
Last Update Posted (Actual)
April 24, 2026
Last Update Submitted That Met QC Criteria
April 23, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2278CE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.